XNAS
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.51 | -526.11 | -103058.83% | $0 | ❌ Miss | -4.80% | +7.26% | — |
| 2026-03-05 | Q4 2025 | -0.66 | -0.49 | +25.76% | $0 | ✅ Beat | +0.51% | -7.68% | -9.91% |
| 2025-11-12 |
| Q3 2025 |
| -0.37 |
| -1.03 |
| -178.38% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
Showing last 3 quarters.